Discussion paper outlines risks, evaluation needs, and oversight options as FDA develops regulatory framework for GenAI‑enabled medical devices.
Discussion paper outlines risks, evaluation needs, and oversight options as FDA develops regulatory framework for GenAI‑enabled medical devices.
Federal health minister seeks assurances that Alberta’s new dual practice system complies with the Canada Health Act as the province prepares for a September rollout.
Epic’s new API lets clinicians instantly see insurer authorization requirements, launching ahead of a 2027 federal interoperability deadline.
The US DOJ memo outlines fraud enforcement priorities, spotlighting healthcare, tax, trade, and corporate misconduct.
Firms should review the FCA’s findings against their own outcomes monitoring approach and identify possible improvements.
Split ruling reinstates DOJ subpoena to gender‑affirming care provider, finding the administration may pursue investigations consistent with its policy agenda.
The SEC’s statement informs public companies that it will discontinue CorpFin’s practice of responding to shareholder proposal no-action requests, effective immediately.
A Commonwealth Fund survey shows affordability is top concern, with differing views on whether government or insurers should lead reforms.